#United States #Pleasanton #Colorectal Cancer #DiaCarta #QuantiDNA

Positive Clinical Trial Results for DiaCarta's Blood Test

In recent developments in molecular diagnostics, DiaCarta Inc., a pioneering company in precision diagnostics, has shared promising outcomes from their clinical trials reported in the Journal of Molecular Pathology. This significant study revolves around the QuantiDNA blood test designed for triaging patients who test positive through the fecal immunochemical test (FIT) in colorectal cancer (CRC) screening. The trial data, published on December 13, 2024, indicates that the QuantiDNA test can effectively reduce the necessity of colonoscopy procedures by 33% for these patients, while maintaining detection rates for serious colorectal lesions comparable to the current standard practices.

The study spanned from 2019 to 2022 and involved 711 participants aged between 50 to 74 years. They were part of a screening initiative led by a public healthcare institution in Naples, Italy. All participants with a positive FIT test were amenable to both the blood-based test and a colonoscopy. This innovative approach aims to ease the strain on healthcare systems by reducing excess colonoscopies, as traditionally, a large percentage of FIT-positive patients—75%, according to previous screenings—end up having negative colonoscopy results.

Dr. Mauro Scimia, DiaCarta's Medical Director and a senior author on the recent publication, emphasized the advantages of this non-invasive blood test, stating, "In Europe, all patients diagnosed as FIT positive are typically referred for colonoscopy, but data indicates that a significant majority do not have any cancer indicators. Utilizing the QuantiDNA test allows us to selectively triage patients, easing the healthcare burden and alleviating patient anxiety while they await procedures."

Echoing this sentiment, Dr. Adam Zhang, the CEO of DiaCarta, expressed satisfaction with the trial results, highlighting the alignment of the QuantiDNA blood test's efficacy with the company's mission of improving cancer diagnostics through liquid biopsy techniques. This clinical trial represents a stride forward in enhancing the tests' clinical application.

About DiaCarta

Founded in Pleasanton, California, DiaCarta specializes in molecular diagnostics, particularly focusing on liquid biopsy technologies. The company's mission revolves around the development of efficacious precision diagnostics that improve patient care and diagnostic accuracy. They have introduced the isobDNA™ technology, which amplifies target sequences and has contributed to a highly sensitive early detection test for colorectal cancer using blood samples.

DiaCarta's innovative approach aims to provide cutting-edge solutions that not only boost detection accuracy but also optimize therapeutic responses in cancer treatment. Their products are covered by medical insurance and are made available through their CAP/CLIA certified laboratory. As an ISO-certified entity, DiaCarta adheres to high operational standards in providing class-leading diagnostic services. Visit their official website at www.diacarta.com for more information on their groundbreaking technologies and services.